Whalesbook
Hester Biosciences reported a 99% rise in consolidated Profit After Tax (PAT) to ₹57.48 crore for FY 2025-26. The company also recommended a dividend of ₹11 per share. This strong profit growth was driven by operational efficiencies and a favorable product mix.
Hester Biosciences Ltd FY26 Profit Soars 99% to ₹57.48 Cr
Consolidated Revenue Up 7% to ₹332.60 Cr; ₹11 Dividend Recommended
Reader Takeaway: Strong profit growth from efficiencies; watch institutional business dependence and credit rating.
What just happened
Hester Biosciences reported a significant 99% year-on-year growth in consolidated Profit After Tax (PAT) for the financial year 2025-26, reaching ₹57.48 crore. Standalone PAT also saw a substantial increase of 64% to ₹52.10 crore. Consolidated revenue grew by 7% to ₹332.60 crore.
Why this matters
The robust profit growth, achieved despite moderate revenue increases, indicates improved operational efficiencies, a favorable product mix, and process standardization. This suggests the company is effectively managing costs and enhancing its margins. The recommended dividend of ₹11 per share (110%) signifies a positive return to shareholders.
The backstory
The company has been investing in its infrastructure, including BSL-3 and Fill-Finish facilities, which were capitalized during FY 2025-26. These investments are aimed at enhancing manufacturing capabilities and supporting future growth. The Poultry Healthcare division continues to be a strong performer, contributing 70% of the total revenue.
What changes now
With the new facilities operational, Hester Biosciences is positioned to scale its manufacturing and potentially expand into commercial and export markets. The receipt of marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine is a key development that could drive future revenue.
Risks to watch
The company's Animal Healthcare segment faced challenges due to delays in government vaccination programs. Dependence on government tenders makes revenue susceptible to procurement cycles. Additionally, CARE Ratings revised its long-term rating to 'CARE BBB/Stable' and short-term rating to 'CARE A3+', indicating a revised view of the company's financial risk profile.
Peer comparison
(No peer comparison data available in the filing.)
Context metrics (time-bound)
- FY 2025-26 Consolidated Revenue: ₹332.60 crore (vs ₹311.10 crore in FY 2024-25)
- FY 2025-26 Consolidated PAT: ₹57.48 crore (vs ₹28.83 crore in FY 2024-25)
- Poultry Healthcare Revenue: ₹206.08 crore (24% YoY growth)
- Animal Healthcare Revenue: ₹81.83 crore
- Recommended Dividend: ₹11 per share
What to track next
Investors will be watching Hester Biosciences' ability to leverage its new facilities for growth, its success in expanding into commercial and export markets to reduce institutional dependence, and the commercialization impact of the H9N2 vaccine.
